African Journal of Cardiology and Cardiovascular Medicine
Editor-in-Chief: Dr. Mohd. Shahbaaz Khan | ISSN: 3136-9294 | Frequency: Biannual | Publication Format: Open Access | Language: English | Indexing/Listing :

Current Issue of African Journal of Cardiology and Cardiovascular Medicine

Volume 1, Issue 1, July 2025
Research Paper

CRISPR-validated PCSK9 pathway variants and lifelong atherosclerotic burden in a familial hypercholesterolemia registry

| Open Access

Daniel K. Armitage1*

Afj.Card.Cardvm. 1(1) (2025) 1-9 DOI: https://doi.org/10.62587/AFJCCM.1.1.2025.1-9
Received: 11/02/2025|Accepted: 25/05/2025|Published: 25/07/2025

Abstract

Background: Many variants identified by genetic testing are variants of uncertain significance and clinical criteria are not perfect at stratifying risk-familial hypercholesterolemia is a lifelong atherosclerotic burden and caused by variants in the PCSK9 pathway that lead to increased LDL cholesterol present from birth. CRISPR editing would, for the first time on a large scale, allow functional validation of variants that could help to improve and refine diagnosis and risk prediction. For this study, functional effects of variants of the PCSK9 pathway were assessed using CRISPR in the context of the lifetime pro-atherosclerotic burden among patients with FH from a registry. Methods: PCSK9-pathway variants found in the registry were functionally proven using PCSK9-CRISPR editing in a hepatocyte model and were categorized as functionally damaging or neutral, based on the difference in LDL uptake compared with wild-type. registry patients were assigned to functional class; differences in untreated LDL, cumulative LDL exposure were evaluated, along with differences in CA and ACSVD with event-free survival analyzed by Cox regression and compared with clinical criteria for discrimination. Results: In total, we detected 30 functionally damaging variants from 56 tested, and functionally validated 17 variants of uncertain significance, with 7 becoming pathogenic and 10 becoming benign. Among 1,080 patients, carriers of functionally damaging variants had a higher untreated LDL (247 versus 150 mg/dL), a greater cumulative LDL exposure, more coronary calcium (median 195 versus 37 Agatston units) and more atherosclerotic disease (35 versus 9%) than variant-negative patients, with a hazard ratio for atherosclerotic events of 4.5 (95% CI 2.8 to 7.1). Functional classification achieved a better discrimination than clinical criteria (the Cstatistic of 0.77 versus 0.72). Conclusion: Functional validation of PCSK9-pathway variants with CRISPR technology reclassified Variants of Uncertain Significance (VUS) and suggested which carriers are most likely to have a large lifelong burden of atherosclerotic disease and events, which complements the use of clinical information and confirms the use of functional genomics for VUS in FHE.


Keywords: Familial hypercholesterolemia, PCSK9, LDL receptor, CRISPR, Variant classification, Atherosclerotic burden, Functional genomics

 Full text  Download  XML